Electronic Supporting Information to

# An injectable *in situ* lipid phase transition system for sustained delivery of dabigatran etexilate with low burst release

Xuanmiao Zhang [a,b], Mei Hu [c], Guangfei Wei [c], Mengdi Jia [c], Tao Gong [c], Ji Liu[a,]

**Cytotoxicity assay**

The cell counting kit-8 assay was used to evaluate the cytotoxicity of DABE-LPTS. Initially, 0.5 mL of DABE-LPTS was added to 5 mL of RPMI-1640 culture media with 10% fetal bovine serum, and incubated at 37 °C for 12 h. After centrifugation, the supernatant of the mixture was taken for a medium extract which was diluted serially using RPMI-1640 with 10% fetal bovine serum to achieve the final concentrations of 1.25, 2.5, 5, 10 and 20%.

L929 cells were seeded in 96-well plates at $4 \times 10^4$ cells/well and incubated for 24 h. Cells were then treated with diluted medium extracts for 24 h. Afterward, 10 µL of CCK-8 solution was added into each well and cells were incubated for another 1 h at 37 °C. The absorbance was measured by a microplate reader at 450 nm. Cell viability (%) was calculated according to the following equation: $(A_{test}/A_{control}) \times 100\%$, where $A_{test}$ and $A_{Control}$ represent the absorbance of cells treated with diluted medium extract and blank culture media, respectively.




Fig.S1. Cytotoxicity profile of L929 cells cultured with the medium extracts of DABE-LPTS. Cells without exposure to samples were used as control. Data represent mean ± SD (n = 6).

## References

1. H. Li, T. Liu, Y. Zhu, Q. Fu, W. Wu, J. Deng, L. Lan, S. Shi. Acta Biomaterialia 2017;**58**:136-145.